title: Response to comment by Juan Segura-Aguilar: New preclinical model are required to discover neuroprotective compound in Parkinson's disease.
authors.affiliation: Department of Pharmacy, University of Naples, Federioco II, Italy. Electronic address: mattace@unina.it.
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Mattace Raso
authors.affiliation: Department of Pharmacy, University of Naples, Federioco II, Italy.
authors.forename: Carmen
authors.initials: C
authors.lastname: Avagliano
authors.affiliation: Department of Pharmacy, University of Naples, Federioco II, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Calignano
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D000066829:Neuroprotection / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D018696:Neuroprotective Agents